Siemens Healthineers AG (SEMHF)
For informational purposes only. Not financial advice. Analysis by Sedat ANAK, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
Siemens Healthineers AG (SEMHF) trades at $40.62 with AI Score 46/100 (Grade C). Siemens Healthineers AG develops, manufactures, and sells a range of diagnostic and therapeutic products and services to healthcare providers globally. Market cap: $45.46B, Sector: Healthcare.
Price live · AI analysis from Mar 16, 2026Analyst Coverage for SEMHF: SEMHF does not currently have published analyst price targets in our coverage universe. This is common for smaller-cap names with limited Wall Street coverage. In the absence of analyst consensus, our AI model evaluates SEMHF against Healthcare peers across nine fundamental dimensions and assigns an underweight signal based on the underlying data.
SEMHF: the 1 perspectives are evenly split.
How is this calculated? →Siemens Healthineers AG (SEMHF) Healthcare & Pipeline Overview
Siemens Healthineers AG is a global leader in medical technology, providing a comprehensive suite of diagnostic and therapeutic products and services. Operating through four segments, the company delivers advanced imaging, in-vitro diagnostics, cancer care technologies, and minimally invasive treatment solutions to healthcare providers worldwide, maintaining a strong market presence with a focus on innovation and integrated healthcare solutions.
What Is the Investment Thesis for SEMHF?
Siemens Healthineers AG presents a notable research candidate driven by its diverse portfolio of medical technology solutions and its strategic positioning within the growing healthcare market. The company's four segments—Imaging, Diagnostics, Varian, and Advanced Therapies—provide a balanced revenue stream and exposure to various high-growth areas within healthcare. With a P/E ratio of 20.43 and a profit margin of 9.1%, Siemens Healthineers demonstrates financial stability and profitability. The company's dividend yield of 2.58% offers an additional incentive for investors. Key growth catalysts include the increasing demand for advanced diagnostic imaging, the expansion of in-vitro diagnostics, and the integration of Varian's cancer care technologies. Potential risks include regulatory changes, technological disruptions, and increased competition. As of 2026, the company's focus on innovation and strategic acquisitions positions it for continued growth and market leadership.
Based on FMP financials and quantitative analysis
SEMHF Key Highlights
- Market capitalization of $45.46B, reflecting strong investor confidence in the company's market position.
- P/E ratio of 20.43, indicating a reasonable valuation relative to earnings.
- Profit margin of 9.1%, demonstrating efficient operations and profitability.
- Gross margin of 38.4%, showcasing the company's ability to maintain healthy profit margins on its products and services.
- Dividend yield of 2.58%, providing a steady income stream for investors.
Who Are SEMHF's Competitors?
SEMHF is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | AI Score |
|---|---|---|---|---|
| ARGNF argenx SE | $803.19 | -10.76% | $49.70B | 49 |
| CHGCF Chugai Pharmaceutical Co., Ltd. | $46.51 | +0.93% | $76.54B | 55 |
| CHGCY Chugai Pharmaceutical Co., Ltd. | $23.26 | -0.47% | $76.56B | 55 |
| CMXHF CSL Limited | $86.80 | +4.35% | $41.57B | 48 |
| HOCPF HOYA Corporation | $154.58 | -8.26% | $51.71B | — |
| DCTH Delcath Systems, Inc. | $13.61 | +3.11% | $469.84M | 73 |
| SSII SS Innovations International, Inc. | $3.76 | -0.53% | $752.49M | 72 |
| RSHUF Respiri Limited | $0.06 | +0.00% | $91.52M | 68 |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are SEMHF's Key Strengths?
- Comprehensive portfolio of diagnostic and therapeutic products and services
- Strong brand reputation and global presence
- Technological innovation and R&D capabilities
- Large installed base of medical equipment
What Are SEMHF's Weaknesses?
- Exposure to regulatory changes and healthcare reforms
- Dependence on Siemens Aktiengesellschaft
- Integration challenges with acquired companies
- Competition from established and emerging players
What Could Drive SEMHF Stock Higher?
- Increasing demand for advanced diagnostic imaging solutions.
- Expansion of in-vitro diagnostics and personalized medicine.
- Integration of Varian's cancer care technologies and solutions.
- Potential regulatory approvals for new medical devices and therapies.
- Growth in digital health and telehealth services.
What Are the Key Risks for SEMHF?
- Regulatory changes and healthcare reforms impacting reimbursement rates.
- Technological disruptions and obsolescence of existing products.
- Increased competition and pricing pressures from established and emerging players.
- Product liability claims and recalls.
- Economic downturns and healthcare budget cuts affecting capital spending.
What Are the Growth Opportunities for SEMHF?
- Expansion of Advanced Diagnostic Imaging: The global diagnostic imaging market is expected to reach $45 billion by 2027, driven by technological advancements and increasing demand for early disease detection. Siemens Healthineers AG can capitalize on this growth by expanding its portfolio of MRI, CT, and molecular imaging systems. The company's innovative technologies, such as AI-powered image analysis, provide a competitive edge in this market. Timeline: Ongoing.
- Growth in In-Vitro Diagnostics: The in-vitro diagnostics (IVD) market is projected to reach $100 billion by 2028, fueled by the rising prevalence of infectious diseases and the increasing adoption of personalized medicine. Siemens Healthineers AG can leverage its Diagnostics segment to expand its IVD offerings, including molecular diagnostics and point-of-care testing solutions. The company's focus on automation and workflow optimization enhances its competitive position. Timeline: Ongoing.
- Integration of Varian's Cancer Care Technologies: The global cancer care market is expected to reach $200 billion by 2029, driven by the increasing incidence of cancer and advancements in treatment modalities. Siemens Healthineers AG can leverage the acquisition of Varian to integrate its cancer care technologies and solutions, offering comprehensive oncology solutions to hospitals and clinics. This integration enhances the company's value proposition and expands its market reach. Timeline: Ongoing.
- Development of Minimally Invasive Therapies: The market for minimally invasive surgical procedures is growing rapidly, driven by the benefits of reduced recovery times and lower complication rates. Siemens Healthineers AG can capitalize on this trend by developing and marketing advanced angiography systems and robotic-assisted platforms for endovascular interventions. The company's focus on image-guided therapies provides a competitive advantage in this market. Timeline: Ongoing.
- Expansion of Digital Health Services: The digital health market is experiencing rapid growth, driven by the increasing adoption of telehealth, remote patient monitoring, and digital therapeutics. Siemens Healthineers AG can expand its digital health services, including consulting, e-learning, and digital solutions for managing treatment and therapy. The company's expertise in medical technology and healthcare workflows positions it well to capitalize on this trend. Timeline: Ongoing.
What Opportunities Does SEMHF Have?
- Expansion in emerging markets
- Growth in digital health and telehealth
- Increasing demand for personalized medicine
- Strategic acquisitions and partnerships
What Threats Does SEMHF Face?
- Technological disruptions and obsolescence
- Economic downturns and healthcare budget cuts
- Increased competition and pricing pressures
- Product liability claims and recalls
What Are SEMHF's Competitive Advantages?
- Technological innovation: Siemens Healthineers AG invests heavily in research and development, resulting in innovative products and solutions that provide a competitive edge.
- Installed base: The company has a large installed base of medical equipment, creating switching costs for customers.
- Brand reputation: Siemens Healthineers AG has a strong brand reputation for quality, reliability, and innovation.
- Comprehensive portfolio: The company offers a comprehensive portfolio of diagnostic and therapeutic products and services, providing a one-stop shop for healthcare providers.
What Does SEMHF Do?
Siemens Healthineers AG, a subsidiary of Siemens Aktiengesellschaft, is a global leader in the healthcare technology sector. The company develops, manufactures, and sells a wide array of diagnostic and therapeutic products and services to healthcare providers worldwide. Its operations are structured into four key segments: Imaging, Diagnostics, Varian, and Advanced Therapies. The Imaging segment offers advanced solutions such as magnetic resonance imaging (MRI), computed tomography (CT), X-ray systems, molecular imaging, and ultrasound systems. The Diagnostics segment provides in-vitro diagnostic products and services for laboratory, molecular, and point-of-care diagnostics, along with workflow solutions for laboratories and informatics products. The Varian segment, acquired in 2021, specializes in cancer care technologies, solutions, and services for oncology departments, including technology-enabled optimized workflows, clinical services, consulting capabilities, and digital solutions. The Advanced Therapies segment focuses on image-guided minimally invasive treatments in cardiology, interventional radiology, and surgery, offering angiography systems and mobile C-arms, including robotic-assisted platforms. Headquartered in Erlangen, Germany, Siemens Healthineers AG has a global presence, serving healthcare providers in numerous countries. The company also provides equipment performance management, clinical education, asset management, and managed departmental services, as well as consulting and digital health services. With a workforce of approximately 72,000 employees, Siemens Healthineers AG is committed to driving innovation and improving healthcare outcomes worldwide.
What Products and Services Does SEMHF Offer?
- Develops and manufactures diagnostic imaging systems, including MRI, CT, X-ray, and ultrasound.
- Provides in-vitro diagnostic products and services for laboratory, molecular, and point-of-care diagnostics.
- Offers cancer care technologies, solutions, and services to oncology departments.
- Develops and markets angiography systems and mobile C-arms for minimally invasive treatments.
- Provides equipment performance management, clinical education, and asset management services.
- Offers consulting and digital health services to healthcare facilities.
How Does SEMHF Make Money?
- Sells diagnostic and therapeutic products to hospitals, clinics, and laboratories.
- Provides service and maintenance contracts for its installed base of medical equipment.
- Offers consulting and digital health services to healthcare providers.
- Generates revenue from the sale of consumables and reagents for diagnostic testing.
What Industry Does SEMHF Operate In?
Siemens Healthineers AG operates in the medical devices industry, which is characterized by continuous innovation, increasing regulatory scrutiny, and evolving healthcare needs. The global medical devices market is projected to reach $600 billion by 2026, driven by an aging population, rising prevalence of chronic diseases, and technological advancements. Siemens Healthineers AG competes with companies like ARGNF (Argonaut Gold Inc), CHGCF (China Gezhouba Group Co Ltd), CHGCY (China Gezhouba Group Co Ltd), CMXHF (CMX Gold & Silver Corp), and HOCPF (Hocan Industrial Co Ltd). The company's comprehensive portfolio and global presence position it well to capitalize on these trends, but it must navigate intense competition and regulatory hurdles to maintain its market leadership.
Who Are SEMHF's Key Customers?
- Hospitals and hospital systems
- Diagnostic imaging centers
- Clinical laboratories
- Oncology departments and cancer centers
- Research institutions
FY2026 estForward Outlook
Wall Street analysts project Siemens Healthineers AG revenue of about $23.67B for fiscal 2026, with EPS near $2.23. The estimate reflects 18 contributing analysts.
SEMHF Valuation & Market Position
With a $45.46B market cap, Siemens Healthineers AG sits in the large-cap segment of the market. Relative to its peer group, SEMHF's quantitative score of 46/100 is roughly in line with the peer average of 52/100.
ROE 12%Key Financial Metrics
Return on equity for Siemens Healthineers AG stands at 11.6%, a gauge of how efficiently it converts shareholder capital into profit. Return on assets is 4.7%, showing how much profit it generates from its asset base. SEMHF trades at a trailing price-to-earnings ratio of 18.76, below the Healthcare sector average of ~23x. Its free cash flow yield is 5.1%, a gauge of the cash the business throws off relative to its market value. A current ratio of 1.10 indicates the company holds enough short-term assets to cover its near-term obligations. Its earnings yield is 5.3%, the inverse of the P/E and a quick read on earnings relative to price.
F-Score 8/9Financial Health
Siemens Healthineers AG's Piotroski F-Score is 8/9, a 9-point checklist of profitability, leverage and efficiency — signaling solid underlying fundamentals. Its Altman Z-Score of 1.81 places it in the grey zone, a middle ground that warrants monitoring.
Company Profile
Siemens Healthineers AG operates in the Medical - Devices industry within the Healthcare sector. It is headquartered in Forchheim, DE. The company is led by CEO Bernhard Montag. SEMHF has traded publicly since 2023.
SEMHF Financials
Fundamental Snapshot
Based on FMP financials and quantitative analysis · FY 2025
Bull Case vs Bear Case
Bull Case
- Comprehensive portfolio of diagnostic and therapeutic products and services
- Strong brand reputation and global presence
- Technological innovation and R&D capabilities
- Large installed base of medical equipment
Bear Case
- Exposure to regulatory changes and healthcare reforms
- Dependence on Siemens Aktiengesellschaft
- Integration challenges with acquired companies
- Competition from established and emerging players
AI-generated arguments based on insider flow, news sentiment and technicals — not financial advice · July 2026
SEMHF Latest News
No recent news available for SEMHF.
SEMHF Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for SEMHF.
Price Targets
Wall Street price target analysis for SEMHF.
SEMHF MoonshotScore
What does this score mean?
The MoonshotScore rates SEMHF's growth potential on a scale of 0-100 across multiple factors including innovation, market disruption, financial health, and momentum.
Leadership: Bernhard Montag
CEO
Bernhard Montag has served as the CEO of Siemens Healthineers AG since 2015. He joined Siemens in 1995 and has held various leadership positions within the company, including Head of the Ultrasound Division and CEO of Imaging & Therapy Systems. Montag holds a degree in physics from the University of Erlangen-Nuremberg and an MBA from the University of Chicago Booth School of Business. His extensive experience in the healthcare technology sector and his strategic vision have been instrumental in driving the growth and success of Siemens Healthineers AG.
Track Record: Under Bernhard Montag's leadership, Siemens Healthineers AG has successfully executed several strategic initiatives, including the acquisition of Varian Medical Systems and the expansion of its digital health offerings. He has overseen the company's transformation into a publicly listed entity and has driven significant revenue growth and profitability improvements. Montag's focus on innovation and customer centricity has strengthened the company's market position and enhanced its competitive advantage.
SEMHF OTC Market Information
Trading on the OTC Other tier signifies that Siemens Healthineers AG (SEMHF) is traded over-the-counter rather than on a major exchange like the NYSE or NASDAQ. OTC markets generally have less stringent listing requirements, resulting in a wider range of companies, including those that may not meet the financial or operational standards of the major exchanges. This tier often includes companies with limited operating history, smaller market capitalization, or those that are foreign-based. Investors should be aware that OTC Other stocks typically involve higher risks due to lower liquidity and less regulatory oversight compared to exchange-listed stocks.
- OTC Tier: OTC Other
- Disclosure Status: Unknown
- Limited liquidity compared to exchange-listed stocks.
- Less stringent regulatory oversight and disclosure requirements.
- Potential for wider bid-ask spreads and greater price volatility.
- Increased risk of fraud or manipulation due to lower regulatory scrutiny.
- Dependence on the parent company, Siemens Aktiengesellschaft.
- Verify the company's financial reporting practices and ensure access to audited financial statements.
- Assess the company's management team and their track record.
- Evaluate the company's competitive position and market share.
- Analyze the company's revenue streams and profitability.
- Review the company's risk factors and potential liabilities.
- Check for any regulatory filings or legal proceedings involving the company.
- Consult with a financial advisor to assess the suitability of the investment.
- Subsidiary of Siemens Aktiengesellschaft, a reputable and well-established company.
- Global presence and operations in multiple countries.
- Comprehensive portfolio of diagnostic and therapeutic products and services.
- Strong brand reputation and technological innovation.
What Investors Ask About Siemens Healthineers AG (SEMHF) — Healthcare
What does Siemens Healthineers AG do?
Siemens Healthineers AG is a leading medical technology company that develops, manufactures, and sells a comprehensive range of diagnostic and therapeutic products and services to healthcare providers worldwide. The company operates through four segments: Imaging, Diagnostics, Varian, and Advanced Therapies. Its offerings include advanced imaging systems, in-vitro diagnostic solutions, cancer care technologies, and minimally invasive treatment options. Siemens Healthineers AG aims to improve healthcare outcomes by providing innovative and integrated solutions to hospitals, clinics, and laboratories.
What do analysts say about SEMHF stock?
Analyst consensus for SEMHF stock is currently neutral, reflecting the company's solid market position and growth prospects balanced against potential risks. Key valuation metrics, such as the P/E ratio of 20.43, suggest a reasonable valuation relative to earnings. Growth considerations include the increasing demand for diagnostic imaging and the integration of Varian's cancer care technologies. Investors should conduct their own due diligence and consider their individual risk tolerance before making any investment decisions.
What are the main risks for SEMHF?
The main risks for SEMHF include regulatory changes and healthcare reforms that could impact reimbursement rates, technological disruptions that could render existing products obsolete, and increased competition from established and emerging players. Additionally, product liability claims and recalls pose a risk to the company's reputation and financial performance. Economic downturns and healthcare budget cuts could also affect capital spending and demand for the company's products and services. Investors should carefully consider these risks before investing in SEMHF.
How does Siemens Healthineers AG navigate regulatory approval processes?
Siemens Healthineers AG navigates regulatory approval processes by maintaining a dedicated regulatory affairs team that works closely with regulatory agencies such as the FDA in the United States and the EMA in Europe. The company has a track record of successfully obtaining regulatory approvals for its medical devices and therapies. Siemens Healthineers AG's strategy involves rigorous testing, comprehensive documentation, and adherence to quality management systems to ensure compliance with regulatory requirements. The company also actively engages with regulatory agencies to stay informed about evolving standards and guidelines.
How does Siemens Healthineers AG manage patent expiration risks?
Siemens Healthineers AG manages patent expiration risks through a combination of strategies, including continuous innovation, patent portfolio management, and lifecycle management. The company invests heavily in research and development to develop new products and technologies that are protected by patents. Siemens Healthineers AG also actively monitors its patent portfolio to identify potential patent expirations and develop strategies to mitigate their impact. These strategies may include extending patent protection through incremental innovations, developing new formulations or delivery systems, or entering into licensing agreements with other companies.
What are the key factors to evaluate for SEMHF?
Siemens Healthineers AG (SEMHF) holds an AI score of 46/100 (low). Not financial advice.
How frequently does SEMHF data refresh on this page?
SEMHF prices update in real time during U.S. market hours. Fundamentals refresh after quarterly filings; analyst ratings and AI insights update daily; news is aggregated continuously.
What has driven SEMHF's recent stock price performance?
Siemens Healthineers AG (SEMHF) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Comprehensive portfolio of diagnostic and therapeutic products and services. See the News tab for the latest drivers. Past performance does not predict future results.
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- Information is based on available data and may be subject to change.
- OTC market data may be less reliable than exchange-listed data.
- AI analysis is pending and may provide additional insights.